Navigation Links
Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
Date:11/10/2008

Changes will result in over $80 million reduction in 2009 cash expenditures

SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced a corporate restructuring that will reduce its San Diego workforce by approximately 25 percent, or 340 employees, and reduce anticipated 2009 cash expenditures by more than $80 million. The restructuring and workforce reduction are part of the Company's business plan to be cash flow positive by the end of 2010. The Company remains fully staffed to grow product revenue from BYETTA(R) (exenatide) injection and SYMLIN(R) (pramlintide acetate) injection and bring exenatide once weekly to market. Amylin's collaboration with Eli Lilly and Company on the global development and commercialization of exenatide is unaffected by the restructuring.

"We've made a difficult, but necessary, decision as a result of factors affecting our business," said Daniel M. Bradbury, president and chief executive officer at Amylin Pharmaceuticals, Inc. "Sales revenues have not met the expectations we had when we scaled up our organization. Today's actions will bring operating expenses more in line with revenue and enable us to continue to achieve our business goals of increasing sales of BYETTA and SYMLIN and bringing exenatide once weekly to market as quickly as possible."

Mr. Bradbury continued, "The restructuring and workforce reductions impact administration, operations, and research and development. We continue to work closely with our partner Lilly to enhance the effectiveness and efficiency of the commercial organization."

The Company's Ohio facility, where exenatide once weekly is manufactured, is unaffected by the restructuring. After the workforce reduction, Amylin's employee base will be 1,800 worldwide, with approximately 900 employees in San Diego.

Today's changes will result in over $100 million reductions in GAAP operating expenses in 2009 and even greater reductions in 2010. The planned 2009 reduction includes employee and nonemployee related costs. As a result of these expense reductions, the Company estimates the use of cash from operations for 2009 will be reduced by more than $80 million. The Company will record a restructuring charge in the fourth quarter, which will primarily include severance and other costs related to workforce reductions.

"We appreciate the significant contributions of those employees affected by today's announcement and are grateful for their efforts and dedication to Amylin's mission," said Mr. Bradbury.

The Company will provide additional details on the restructured organization and longer-term financial benefits of these changes with the issuance of its 2009 financial guidance during its 2008 year-end results conference call in January 2009.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. The Company's actual results could differ materially from those discussed due to a number of risks and uncertainties, including the risk that our revenues may not grow or ever become sufficient to cover our costs after the planned restructuring; that our cost reductions may not be as large as we expect; that our efforts to work more efficiently with Eli Lilly and Company may not be successful; that our product candidates, including exenatide once weekly, may not receive regulatory approval; and inherent scientific, regulatory and other risks in the drug development and commercialization process. These and additional risks and uncertainties are described more fully in the Company's most recently filed SEC documents, including its Form 10-Q. Amylin undertakes no duty to update these forward-looking statements.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
2. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Webcast Third Quarter Results
5. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
6. Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
7. Amylin and Lilly Set Date and Time for Conference Call
8. Amylin Pharmaceuticals to Webcast Second Quarter Results
9. Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
10. Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
11. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):